http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
IMPROVEMENT OF TRANSIENT OPERATION CONTROLLABILITY IN ENGINE TEST BENCH FOR HEAVY-DUTY VEHICLES
Norifumi Mizushima,Shigeo Sato,Hiroyuki Yagi,Hisakazu Suzuki 한국자동차공학회 2019 International journal of automotive technology Vol.20 No.6
In this study, two kinds of control methods for the transient operation of an engine test bench for heavy-duty vehicles were applied in the JE05 test cycle and World Harmonized Transient Cycle (WHTC) test conditions in order to evaluate the controllability of transient operations and the effect on emissions. One control method uses dynamometer torque with its inertia correction as the feedback signal (dyno torque F/B control); the other method uses axial torque measured by a flange-type high-response torque meter as the feedback signal (axial torque F/B control). The transient operation controllability using the axial torque F/B control improved compared with the dyno torque F/B control. The results influence NOx emissions in the emissions test cycle, such as JE05 and WHTC, with the engine test bench. Axial torque F/B control could become a more useful technique when it is required to improve the reproducibility of real driving conditions.
Yoshio Hirayasu,Shin-Ichi Sato,Norifumi Shuto,Miwa Nakano,Teruhiko Higuchi 대한신경정신의학회 2017 PSYCHIATRY INVESTIGATION Vol.14 No.1
Objective: The aim of the present study was to perform a subgroup analysis of data from a phase II global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of bitopertin, a glycine reuptake inhibitor that activates N-methyl- D-aspartate receptors by increasing the concentration of glycine in the synaptic cleft, in Japanese and non-Japanese patients with schizophrenia and predominant negative symptoms. Methods: Patients with schizophrenia and predominant negative symptoms on one or two antipsychotic drugs, including atypical antipsychotic drugs (olanzapine, risperidone, quetiapine, aripiprazole, and paliperidone) as the primary treatment, received bitopertin (10, 30, or 60 mg/day) or placebo once daily for 8 weeks as an add-on treatment. Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) negative symptom factor score (NSFS). Results: The efficacy of bitopertin (10 mg and 30 mg) was similar between Japanese and non-Japanese patients. In the bitopertin 60-mg group, no difference from the placebo group was observed in Japanese or non-Japanese patients. The response to placebo was lower in Japanese patients, and there was a trend towards a greater difference in the change in PANSS NSFS between the placebo group and the 10- mg and 30-mg groups among Japanese patients. The safety profile of bitopertin was favorable in Japanese and non-Japanese patients. Conclusion: According to this subgroup analysis from a global phase II study of bitopertin, there was no difference in terms of efficacy and safety between Japanese and non-Japanese patients.
Anti-fibrotic treatments for chronic liver diseases: The present and the future
( Naoshi Odagiri ),( Tsutomu Matsubara ),( Misako Sato-matsubara ),( Hideki Fujii ),( Masaru Enomoto ),( Norifumi Kawada ) 대한간학회 2021 Clinical and Molecular Hepatology(대한간학회지) Vol.27 No.3
Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of liver sinusoidal endothelial cells, stimulation of immune cells including macrophages and Kupffer cells, and activation of hepatic stellate cells (HSCs), resulting in progression of liver fibrosis. Liver cirrhosis is the terminal state of liver fibrosis and is associated with severe complications, such as liver failure, portal hypertension, and liver cancer. Nevertheless, effective therapy for cirrhosis has not yet been established, and liver transplantation is the only radical treatment for severe cases. Studies investigating HSC activation and regulation of collagen production in the liver have made breakthroughs in recent decades that have advanced the knowledge regarding liver fibrosis pathophysiology. In this review, we summarize molecular mechanisms of liver fibrosis and discuss the development of novel anti-fibrotic therapies. (Clin Mol Hepatol 2021;27:413-424)